Загрузка...
Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publishing
2011-03-01
|
| Серии: | Therapeutic Advances in Neurological Disorders |
| Online-ссылка: | https://doi.org/10.1177/1756285611403960 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|